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Abstract
The renin–angiotensin–aldosterone (RAA) system and the endothelin (ET) system entail the most potent vasopressor mechanisms
identiﬁed to date. Although they were studied in depth in relation to arterial hypertension and cardiovascular diseases, limited information
on their interrelationships in causing hypertension and related target organ damage exists. The identiﬁcation of consensus sequences for
jun in the regulatory region of the preproendothelin-1 (ppET-1) gene raised the possibility of its transcriptional regulation by angiotensin
II (Ang II). This was conﬁrmed by the ﬁnding that stimulation with Ang II of cultured vascular smooth muscle cells (VSMCs) and
endothelial cells (ECs) induced expression of the ppET-1 gene and synthesis of ET-1. Endogenously produced ET-1 was found to
contribute to the hypertrophic response of cardiomyocytes to Ang II and thereby to cardiac hypertrophy. Furthermore, ET-1 exerts
multifaceted effects on the RAA system, such as dose-dependent inhibition of renin synthesis, and stimulation of aldosterone secretion.
The ﬁnding of abundant speciﬁc ET-1 receptors in the adrenocortical zona glomerulosa (ZG) suggested a direct secretagogue effect of
ET-1. In rats, ET receptors mediate such an effect, whilst in humans, both ET and ET receptor subtypes intervene in regulating the B AB
transcription of the aldosterone synthase gene. In addition, ET-1 stimulates DNA synthesis and proliferation of ZG cells via ET receptors A
and, therefore, might play a role in cell turnover of the normal adrenal cortex and in the onset of adrenal tumours. Studies on the in vivo
interactions between ETs and the RAA system have given conﬂicting results, insofar as some suggested a participation of ET-1 in the
pressor and cellular effects of exogenously administered Ang II, whereas others did not in the transgenic TGR(Ren 2m)27 rats and in the
two-kidney, one clip. Ó 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction with emphasis on the role of endothelin-1 (ET-1) in the
regulation of the RAAS and on in vivo studies supporting
The renin–angiotensin–aldosterone system (RAAS) and a co-operation of both systems in the regulation of
the endothelin (ET) system are two of the most potent cardiovascular and adrenocortical function.
vasopressor mechanisms identiﬁed to date (for a review,
see [1–3]). Therefore, it is not surprising that they have
been investigated extensively in relation to arterial hy- 2. Potential sites of interaction
pertension and related cardiovascular disease. However,
despite this vast body of investigations, only limited Several potential sites of interaction between the RAAS
information exists on their reciprocal relationships. Thus, and ET system, spanning from the molecular level to the in
in this paper, we shall review available knowledge on the vivo hormonal and haemodynamic regulation, can be
interactions between these two important pressor systems, envisaged. It has been hypothesised that Ang II, the active
peptide of the RAAS, affects the synthesis of ET-1, which,
in turn, can inﬂuence the RAAS by acting at different steps *Corresponding author. Tel.: 139-49-821-3304 or 2301; fax: 139-49-
880-2252.
E-mail address: gprossi@ux1.unipd.it (G.P. Rossi) Time for primary review 29 days.
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Fig. 1. Possible mechanisms of ET-1-induced inhibition of renin. ZG, adrenocortical zona glomerulosa cells; JG, juxtaglomerular cells; PLC,
phospholipase C; PKC, protein kinase C; PKA, protein kinase A; TGF-b, transforming growth factor b; AVP, arginine–vasopressin. Plus and minus signs
indicate activation and inhibition, respectively.
(Fig. 1). In keeping with this hypothesis, consensus
sequences for jun were identiﬁed in the regulatory regions
of the preproendothelin-1 (ppET-1) gene [4], suggesting
the possibility of transcriptional regulation of this gene by
factors acting through the G-protein–phospholipase C–
protein kinase C pathway (Fig. 2) [5,6].
Of interest, an additional site of interaction between the
RAAS and ET system has recently been identiﬁed at the
level of ET-1 biosynthesis. Although the predominant ET
biosynthetic pathway involves the speciﬁc cleavage of
pro(big)ET-1 by ECE-1, the possibility that bigETs are
also cleaved by human chymase, the enzyme responsible
for most of the conversion of Ang I to Ang II in the
myocardium [7] (Fig. 2), has been suggested, based on the
observation that the rat chymase was shown to cleave
31 32 bigETs at the Try –Gly bond [8], leading to novel 1–31
endothelin isopeptides, ETs(1–31). The latter were shown
in vitro to exert a less potent but slower-developing and a
longer-lasting contraction than ETs(1–21) in porcine cor-
onary artery and rat aorta. Interestingly, at variance with
ET-1, this vasoconstriction of ETs(1–31) was also found
to be inhibited by either the ET antagonist BQ-485 or the A
ET antagonist BQ-788 and, therefore, these novel pep- B
tides might act in a different manner from endothelins [9],
possibly through different receptors.
ET-1 was found to exert multifaceted effects on the
RAAS, such as dose-dependently inhibiting renin pro-
duction, directly stimulating aldosterone production from Fig. 2. Schematic representation of the biosynthetic pathways of the
the adrenocortical zona glomerulosa (ZG) [10,11] and endothelins showing a role for chymase, the main Ang II-forming enzyme
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might be relevant for the regulation of both function and hypertrophy, the data suggesting an effect of the peptide on
cell turnover of the adrenal cortex under physiological and ET-1 transcription raised the possibility that ET-1 might
pathophysiological conditions. also intervene in hypertension-related left ventricular hy-
pertrophy and remodelling. This contention is supported by
the observation that endogenously produced ET-1 con-
3. Effect of the RAAS on endothelin-1 tributed to the hypertrophic response of cardiomyocytes to
both Ang II and ET-3 [17]. Thus, ET-1 antagonism may
The identiﬁcation of consensus sequences for regulatory offer an additional weapon for therapeutic interventions
elements in the regulatory region of both the ppET-1 gene aimed at preventing cardiovascular damage. The demon-
(Fig. 3) and the endothelin converting enzyme 1 (ECE-1) stration that long-term treatment with ET antagonists not
gene suggested the possibility that both of these key-genes only greatly improved the survival of rats with chronic
involved in ET-1 biosynthesis are regulated by the same heart failure, but also prevented ventricular remodelling,
factors. The hypothesis that Ang II can turn on the i.e., the increase in left ventricular mass and cavity
transcription of the ppET-1 gene is supported by the in enlargement [19], as well as the increase in collagen
vitro ﬁndings that human and porcine cultured vascular density [20], strongly supports this view.
smooth muscle cells (VSMCs) [12–14] and endothelial
cells (ECs) [15,16] can express the preproET-1 gene and
synthesise immunoreactive (ir) ET-1 upon stimulation with
Ang II. Evidence indicates that Ang II turns on the 4. Effect of ET-1 on the RAAS
transcription of the ppET-1 gene by acting via AT-1
receptors linked to activation of transcription via activator Besides its potent haemodynamic effects, the intraven-
protein-1/kinase C-mediated mechanisms [14,15,17,18]. ous infusion of ET-1 in animals and humans was found to
However, the possibility of complex cross-talk between deeply affect the RAAS. Renin secretion from juxtag-
several signalling pathways that can be activated by a lomerular cells was generally decreased by ET-1 both in
number of humoral factors, such as insulin, catechol- vitro and in vivo, as shown by seven out of eight available
amines, components of the clotting/ﬁbrinolysis cascade, studies [21–28]. Collectively, available evidence is con-
and cytokines, as depicted in Fig. 3, should be kept in sistent with both a direct and an indirect inhibitory action
mind when interpreting results of in vivo studies. of ET-1, through mechanisms that are depicted in Fig. 1.
Since Ang II is a well known promoter of cardiac This inhibition may be relevant in a number of clinical
Fig. 3. Schematic representation of the intracellular signalling mechanisms whereby Ang II can turn on the transcription of the preproET-1 gene via
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situations, for instance, in pregnancy-induced hyperten- ure, malignant and severe hypertension, endotoxaemia and
sion, a vasospastic and volume-reduced disorder where in transplant recipients.
endothelial cell damage is suspected to play an important
role. Compared to normal pregnancy, pregnancy-induced
hypertension was found to be associated with a two-fold 5. In vivo interactions of ET-1 and the RAAS
increase in plasma irET-1 levels, which may be respon-
sible for the inappropriately low plasma renin activity in To investigate whether the aforementioned in vitro
relation to the reduced plasma volume [28]. interactions between ET-1 and RAAS have an in vivo
The observation that, despite this inhibitory effect on counterpart, a number of studies have been carried out.
renin, ET-1 was found to markedly stimulate aldosterone Among the original observations stimulating these in-
secretion both in animals and in humans, suggested a direct vestigations was the report that subthreshold concentra-
effect of the peptide on the adrenal cortex (for review, see tions of ET-1, i.e., lower than the concentration range
Ref. [10]). This contention was conﬁrmed by ﬁndings of (30–300 pM) needed to elicit a contractile response, were
abundant speciﬁc ET and ET receptors in the human and able to potentiate the vasoconstrictor response to well AB
animal adrenal ZG [29–31] as well as by in vitro studies known vasoconstrictors, such as serotonin and histamine
[32–35], which clearly indicated that, in rats, the ET [43]. In male HanRen2/Edin rats derived from crossing B
receptor subtype mediates the direct secretagogue effect of the homozygote transgenic TGR(mREN-2)27 with Edin-
ET-1 on aldosterone [36]. At variance with ﬁndings in rats, burgh Sprague-Dawley rats, which show a 73.5% inci-
available data in humans indicate that both the ET and dence of the malignant phase of hypertension, an increased A
ET receptors are involved [37] in the transcriptional ET-1 mRNA content was found in the kidney in the B
regulation of the aldosterone synthase gene, both in animals that developed malignant hypertension [44]. None-
adrenocortical carcinoma and in normal human adrenal theless, no effect of the mixed ET /ET endothelin AB
cells [38]. Similar results were recently obtained by antagonist bosentan [45] was seen on blood pressure. At
another group working independently [39]. Of interest, in variance with these ﬁndings, bosentan pre-treatment was
vitro in dispersed normal human adrenocortical ZG cells, capable of blunting the increase in blood pressure, the fall
as well as in Conn’s adenoma cells, ET-1 was found to be in cardiac output, and the decrease in arterial conductance
equipotent to Ang II [38], the most important physiological evoked by an infusion of Ang II, both in WKY and in SHR
secretagogue of aldosterone identiﬁed so far. Further rats [46]. This blunting was more pronounced in SHR rats,
experiments from our group provided unequivocal evi- even thought it was seen in both strains, but it was evident
dence that, in the rat adrenal ZG, by acting via ET at the lower (2–10 ng/kg/min) but not at the higher (.30 A
receptors, ET-1 stimulates both DNA synthesis and cell ng/kg/min) doses of Ang II, thereby suggesting the
proliferation [40]. Since these latter effects were dose- possibility of an ET-1 component only in the initial pressor
dependently blunted by the protein-kinase C inhibitor effect of Ang II. In partial agreement with this contention,
Ro31-8220 and by the tyrosine-kinase inhibitor tyrphostin- a ﬁve-day-infusion of Ang II (0.7 mg/kg/day) to Sprague-
23, they are likely to involve activation of both of these Dawley rats was found to markedly enhance immuno-
kinase signalling pathways, but not the protein-kinase A, staining for ET-1 in VSMCs; furthermore, administration
cyclooxygenase and lipoxygenase signalling pathways of the ET -selective antagonist PD 155080 abolished the A
[40]. Based on these ﬁndings, we hypothesised that ET-1 rise in blood pressure, as did the Ang II AT-1 receptor
may enhance the growth of the entire adrenal gland by antagonist losartan [47]. In 1997, a number of studies
¨ acting on the ‘cambium’ layer of cells endowed with ET carried out in Dr. Luscher’s laboratory suggested that ET-1 A
receptors, which are mainly located in the ZG. [41]. could play an important role in the structural changes
However, in recent in vivo experiments in rats, it was induced by Ang II infusion. Two weeks of Ang II infusion
found that the administration of the ET -speciﬁc antago- (200 ng/kg/min) increased media thickness, the media– A
nist BQ-123 and the mixed ET /ET antagonist bosentan lumen ratio and the cross-sectional area of the mesenteric AB
for four weeks did not affect adrenal gland weight, casting and cerebral arterioles, and nearly doubled the content of
doubts on the relevance of ET-1 in the maintenance of the ET-1 in the mesenteric tissue, through mechanisms most
volume of the entire gland in this species (for review, see likely involving the ET receptor, inasmuch as the speciﬁc A
Ref. [42]). antagonist LU135252 was able to prevent both the de-
Thus, collectively, these data indicate that ET-1 potently velopment of medial hypertrophy and increased peptide
stimulates aldosterone secretion and suggest that it may content in both types of vessels [48]. It was also shown
affect adrenocortical growth through a direct action on that a two-week-infusion of a similar dose of Ang II led to
speciﬁc receptors, albeit with differences among species. enhanced vascular endothelin converting enzyme activity
These effects of ET-1 are potentially relevant in several and renal ET-1 content in WKY rats [49] and that
conditions where endothelial damage, hypertension and LU135252 lowered the Ang II-induced pressure increase
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hypothesis that ET-1 might play a role not only in the closely paralleled those of their systolic blood pressure,
haemodynamic effects of Ang II but also in the mecha- thereby suggesting a role for ET-1 in this form of renin-
nisms of related cardiovascular damage, is further sup- dependent hypertension [55], in agreement with previous
ported by three sets of observations. First, bosentan reports [56]. However, in contrast with this contention and
entirely prevented the development of hypertension, the in keeping with the aforementioned results in the
reduction in renal blood ﬂow and the marked increase in HanRen2/Edin rats cross [44], bosentan did not have
albuminuria and heart weight induced by a ten-day infu- either a blood-pressure-lowering effect or any effectiveness
sion of Ang II (200 ng/kg/min) [51]. Second, in a canine in preventing left ventricular and vascular hypertrophy in
model of Page (kidney wrapping) hypertension, bosentan male heterozygote TGR(mREN-2)27 rats. These ﬁndings
was found to exert a hypotensive effect in addition to that were in sharp contrast with the efﬁcacy of the angiotensin
of the AT-1 receptor antagonist losartan [52]. This additive II AT-1 receptor antagonist irbesartan in lowering blood
hypotensive effect was found also in a study on rats with pressure and preventing left ventricular and arteriolar
renin-dependent hypertension [53]. hypertrophy in the same model. Thus, it would appear that
An animal model that lends itself to the investigation of in this form of severe hypertension, due to overexpression
the interactions between the RAA and ET systems in vivo of a renin gene, ET-1 does not play any major role. This
is the TGR(mREN-2)27 rat. In this model, the introduction conclusion is only partially supported by ﬁndings in two-
into the rat genome of the mouse Ren-2 gene, encoding for kidney one-clip hypertension rats. In this animal model of
renin, causes severe hypertension, which is associated with renovascular hypertension, the orally active endothelin
overexpression of the transgene in several tissues, par- antagonist Ro-00203, whilst having no signiﬁcant effect on
ticularly in the adrenal cortex and the vessel wall, with renin secretion and renin gene expression, attenuated the
ensuing enhanced endogenous production of Ang II in rise in blood pressure elicited by clipping one renal artery,
tissues and low plasma renin activity [54]. A marked although it did not abolish it [57].
sexual dimorphism of blood pressure changes exists in this The reasons why ET-1 may take part in hypertension
model. In fact, while males develop severe hypertension, induced by exogenously administered Ang II, but not in
which is fulminant in homozygotes and somehow less the models with an enhanced endogenous production of
severe in heterozygotes, the female TGR(mREN-2)27 rats Ang II, are unclear at present. They might depend upon the
have a milder form of hypertension, which in different tissue levels attained by Ang II and/or the
heterozygotes peaks at approximately ten weeks of age and different gradients between the bloodstream, endothelium
then spontaneously returns to normal values by 35 weeks and VSMCs of the blood vessels’ tunica media, in these
of age. Thus, these heterozygote female rats can be two situations. In fact, it is well documented that, in
maintained without any antihypertensive treatment. Of heterozygote TGR(mREN-2)27 rats, a high tissue expres-
interest, we recently reported that, in these female animals, sion of Ang II occurs together with low plasma Ang II,
the aortic responsiveness to ET-1 followed changes that whilst in the models with exogenous Ang II administra-
Fig. 4. Endothelin-1-dependency of hypertension in different experimental animal models (see Ref. [58] for review) on an arbitrary scale. Regardless of the
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tion, the peptide concentrations are likely to be high in 260 mmHg and, thus, almost normalised blood pressure.
plasma and lower in tissues. Thus, the combined ET/RAAS inhibition may provide an
In contrast with the controversial data on the in- interesting synergistic potential in terms of blood pressure
volvement of ET-1 in renin-dependent forms of hyperten- reduction. Of further interest, this synergism was found
sion, rather concordant data on the role of the peptide in also in patients with class III New York Heart Association
mineralocorticoid-dependent forms of hypertension exist (NYHA) congestive heart failure, who were haemodynam-
(for a review, see Ref. [58]). Increased levels of irET-1 ically stable on ACE inhibitors and diuretics, in whom the
were found both in plasma and in the arterial wall of rats mixed ET /ET receptor antagonist bosentan elicited a AB
with deoxycorticosterone acetate (DOCA)-salt-induced clear-cut decrease in systemic and pulmonary vascular
hypertension [59–61]. Elegant in situ hybridisation studies resistance along with an increase in the cardiac index [67].
by Day et al. [62] showed enhanced expression of the
ppET-1 gene in the vessel wall in the same model.
Treatment with bosentan was quite effective in preventing 7. Conclusions and perspectives
vascular hypertrophy in this model. This ﬁnding lent
further support to the contention of a direct involvement of The identiﬁcation of ET-1 by Yanagisawa et al. [68] one
ET-1 in target organ damage in this low-renin form of decade ago has added a novel important player to the
hypertension [63]. The contention that ET-1 plays an ‘arena’ of potential mechanisms causing arterial hyperten-
important role in salt-dependent forms of hypertension is sion and related cardiovascular disease. Over the years, it
further supported by the ﬁndings of Barton et al. [64], who has been increasingly appreciated that any newly discov-
reported that the ET -speciﬁc antagonist LU135252 was ered agent cannot be investigated singularly, but rather A
able to partially prevent the development of hypertension should be assessed in the context of all the other known
and the structural and functional alterations caused by mechanisms. There are several interactions between the
chronic salt administration in Dahl salt-sensitive rats. A RAAS and the endothelin system, which may have rel-
role for ET-1 in cardiovascular damage of salt-sensitive evant effects on blood pressure and on hypertension-
hypertension is suggested also by data obtained in humans related complications. Experimental research has started to
[65]. unravel these interactions, and pilot clinical trials gave
Fig. 4 summarises available data on the participation of promising results, but the question of whether or not they
endothelin in experimental models of hypertension. It must are also relevant in humans in the clinical setting and have
be pointed out, however, that regardless of the initial ET-1 therapeutic implications needs to be investigated further.
dependency of hypertension, the pathogenic role of the ET
system is deemed to get more and more important as
endothelial and target organ damage supervene. References
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